ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in ovarian and endometrial cancers

CAR-T Digest - August 2020

Weekly Digest - May 2026

07 May 2026: ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in Ovarian and Endometrial cancers

ArriVent BioPharma has received IND clearance for ARR-002, a potential first-in-class tetravalent ADC targeting both MUC16 and NaPi2b, initially advancing in Ovarian and Endometrial cancers
ARR-002 is designed with a dual-target tetravalent approach intended to improve tumor binding and payload delivery while potentially reducing off-tumor toxicity compared with conventional single-target ADCs
Preclinical findings presented at the AACR Annual Meeting 2026 demonstrated strong dual-target engagement and enhanced internalization versus single-target antibody controls
In animal studies, ARR-002 showed superior antitumor activity in Ovarian cancer models and encouraging tolerability in cynomolgus monkeys, supporting the potential for a broader therapeutic window
With IND clearance secured, ArriVent plans to initiate a Phase 1 study in the second half of 2026, further expanding its pipeline of next-generation ADCs for solid tumors